JOHNSON & JOHNSON 8K

Johnson & Johnson reported strong Q2 2026 results and raised its full-year 2026 sales and adjusted EPS guidance, supported by robust segment performance and a series of pipeline, regulatory, and strategic updates.

On July 15, 2026, Johnson & Johnson reported its second-quarter 2026 results, highlighting 6.6% reported sales growth to $25.3 billion, diluted EPS of $2.27 and adjusted EPS of $2.90, solid operational growth in both its Innovative Medicine and MedTech segments, and strong free cash flow, and, based on this performance, raised its full-year 2026 guidance for reported sales to approximately $101.1 billion and adjusted EPS to $11.68 at the midpoint while underscoring a robust pipeline with multiple recent FDA and CE approvals, key late-stage data readouts, and strategic portfolio moves including M&A, investments, and leadership appointments.

Filing Facts

CIK

200406

Ticker

JNJ

Form

8K

Source Type

fda

Accession

0000200406-26-000146

Alert Tier

7